Literature DB >> 18607510

Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis.

James A DeVoti1, David W Rosenthal, Rong Wu, Allan L Abramson, Bettie M Steinberg, Vincent R Bonagura.   

Abstract

Recurrent respiratory papillomas (RRP) are benign airway tumors, caused primarily by human papillomaviruses (HPV) types 6 and 11. The disease is characterized by multiple recurrences after surgical removal, with limited effective therapy. To identify novel targets for future therapy, we established transcriptional profiles for actively growing papillomas compared with autologous, clinically normal, laryngeal epithelia (adjacent tissue). Total ribonucleic acid (RNA) from 12 papillomas and 12 adjacent tissues were analyzed by microarray, and the matched sets of tissues compared by paired t test, to identify differentially expressed genes in papilloma tissues while minimizing variations intrinsic to individual patients. Quantitative polymerase chain reaction (PCR) was used to confirm the relative expression levels for a subset of genes. Within the 109 differentially expressed transcripts whose expression varied at least three-fold were two large groups of genes with related functions. The first group consisted of 18 genes related to host defense, including both innate and adaptive immunity. The second group contained 37 genes that likely contribute to growth of papillomas as benign tumors, since the altered pattern of expression also had been reported previously in many cancers. Our results support our previous studies that document a systemic T(H)2-like adaptive immune response in RRP, and suggest that there is a role for altered innate immunity in RRP as well. We propose that HPV 6 and 11 infection establishes a tumorigenic microenvironment characterized by alteration of both innate inflammatory signals and adaptive immune responses that prevent effective T(H)1-like response, in conjunction with altered expression of numerous genes that regulate cellular growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607510      PMCID: PMC2442987          DOI: 10.2119/2008-00060.DeVoti

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  46 in total

1.  Laryngeal papillomatosis: clinical, histopathologic and molecular studies.

Authors:  A L Abramson; B M Steinberg; B Winkler
Journal:  Laryngoscope       Date:  1987-06       Impact factor: 3.325

2.  HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Andrea Vambutas; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; Mark J Shikowitz; David W Gjertson; Elaine F Reed
Journal:  Hum Immunol       Date:  2004-08       Impact factor: 2.850

3.  Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11.

Authors:  Andrea Vambutas; Vincent R Bonagura; Elaine F Reed; Allan L Abramson; Virginia Mullooly; James DeVoti; David W Gjertson; Bettie M Steinberg
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

4.  Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx.

Authors:  P Mounts; K V Shah; H Kashima
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

5.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

6.  Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin.

Authors:  P Madsen; H H Rasmussen; H Leffers; B Honoré; K Dejgaard; E Olsen; J Kiil; E Walbum; A H Andersen; B Basse
Journal:  J Invest Dermatol       Date:  1991-10       Impact factor: 8.551

Review 7.  A review of the S100 proteins in cancer.

Authors:  I Salama; P S Malone; F Mihaimeed; J L Jones
Journal:  Eur J Surg Oncol       Date:  2007-06-13       Impact factor: 4.424

8.  Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers.

Authors:  L Gissmann; L Wolnik; H Ikenberg; U Koldovsky; H G Schnürch; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

9.  Bladder squamous cell carcinomas express psoriasin and externalize it to the urine.

Authors:  J E Celis; H H Rasmussen; H Vorum; P Madsen; B Honoré; H Wolf; T F Orntoft
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

10.  Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis.

Authors:  V R Bonagura; F P Siegal; A L Abramson; F Santiago-Schwarz; M E O'Reilly; K Shah; D Drake; B M Steinberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-05
View more
  31 in total

1.  Interferon-γ Treatment of Human Laryngotracheal Stenosis-Derived Fibroblasts.

Authors:  Kevin Motz; Idris Samad; Linda X Yin; Michael K Murphy; Madhavi Duvvuri; Dacheng Ding; Alexander T Hillel
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-11-01       Impact factor: 6.223

2.  Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

Authors:  James DeVoti; Lynda Hatam; Alexandra Lucs; Ali Afzal; Allan Abramson; Bettie Steinberg; Vincent Bonagura
Journal:  Mol Med       Date:  2014-08-28       Impact factor: 6.354

3.  Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs.

Authors:  Ravisankar A Ramadas; Susan L Ewart; Benjamin D Medoff; Ann Marie LeVine
Journal:  Am J Respir Cell Mol Biol       Date:  2010-03-18       Impact factor: 6.914

4.  Genetic dysregulation in recurrent respiratory papillomatosis.

Authors:  Regina Rodman; Simukayi Mutasa; Crystal Dupuis; Heidi Spratt; Michael Underbrink
Journal:  Laryngoscope       Date:  2014-03-11       Impact factor: 3.325

5.  Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.

Authors:  Ben C Creelan; M Usman Ahmad; Frank J Kaszuba; Farah K Khalil; Allison W Welsh; Metin Ozdemirli; Nazaneen N Grant; Deepa S Subramaniam
Journal:  Oncologist       Date:  2019-03-06

6.  Constitutive overexpression of the oncogene Rac1 in the airway of recurrent respiratory papillomatosis patients is a targetable host-susceptibility factor.

Authors:  Alexandra V Lucs; Rong Wu; Virginia Mullooly; Allan L Abramson; Bettie M Steinberg
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

7.  T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.

Authors:  David W Rosenthal; James A DeVoti; Bettie M Steinberg; Allan L Abramson; Vincent R Bonagura
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

Review 8.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

9.  Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Zeying Du; Elham Ashouri; Lihui Luo; Lynda J Hatam; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; David W Gjertson; Elaine F Reed; Raja Rajalingam
Journal:  Hum Immunol       Date:  2009-10-25       Impact factor: 2.850

Review 10.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.